• 1
    Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 80611.
  • 2
    Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001; 20: 687788.
  • 3
    Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404: 2936.
  • 4
    Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD, Lamet K et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441: 11114.
  • 5
    Golsteyn RM, Mundt KE, Fry AM, Nigg EA. Cell cycle regulation of the activity and subcellular localization of PLK1, a human protein kinase implicated in mitotic spindle function. J Cell Biol 1995; 129: 161728.
  • 6
    Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996; 135: 170113.
  • 7
    Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rubsamen-Waigmann H, Strebhardt K. Prognostic significance of Polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997; 14: 5439.
  • 8
    Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005; 24: 28791.
  • 9
    Weichert W, Denkert C, Schmidt M Gekeler V, Wolf G, Kobel M, Dietel M, Hauptmann S. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004; 90: 81521.
  • 10
    Cogswell JP, Brown CE, Bisi JE, Neill SD. Dominant-negativepolo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ 2000; 11: 61523.
  • 11
    Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis of cancer cells. Proc Natl Acad Sci USA 2003; 100: 578994.
  • 12
    Elez R, Piiper A, Kronenberger B, Kock M, Brendel M, Herrmann E, Pliquett U, Neumann E, Zeuzem S. Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene 2003; 22: 6980.
  • 13
    Elez R, Piiper A, Giannini CD, Brendel M, Zeuzem S. Polo-like kinase1, a new target for antisense tumor therapy. Biochem Biophys Res Commun 2000; 269: 3526.
  • 14
    Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005; 65: 2698704.
  • 15
    Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, Jiang J, Holland J, Reddy EP. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005; 7: 27586.
  • 16
    Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006; 26: 2093108.
  • 17
    Reagan-Shaw S, Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J 2005; 19: 61113.
  • 18
    Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, Yokota A, Segawa H, Toda Y, Kageyama S, Yoshiki T, Okada Y, Maekawa T. Intravesical administration of small interfering RNA targeting PLK1 successfully prevents the growth of bladder cancer. J Clin Invest 2005; 115: 97885.
  • 19
    Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell 2006; 126: 2315.
  • 20
    Raemdonck K, Remaut K, Lucas B, Sanders NN, Demeester J, De Smedt SC. In situ analysis of single-stranded and duplex siRNA integrity in living cells. Biochemistry 2006; 45: 1061423.
  • 21
    Haupenthal J, Baehr C, Kiermayer S, Zeuzem S, Piiper A. Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem Pharmacol 2006; 71: 70210.
  • 22
    Piiper A, Dikic I, Lutz MP, Leser J, Kronenberger B, Elez R, Cramer H, Muller-Esterl W, Zeuzem S. Cyclic AMP induces transactivation of the receptors for epidermal growth factor and nerve growth factor thereby modulating activation of MAP kinase, Akt and neurite outgrowth in PC12 cells. J Biol Chem 2002; 277: 4362330.
  • 23
    Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 1738.
  • 24
    Lee FS, Vallee BL. Structure and action of mammalian ribonuclease (angiogenin) inhibitor. Prog Nucleic Acid Res Mol Biol 1993; 44: 130.
  • 25
    Marques JT, Devosse T, Wang D, Zamanian-Daryoush M, Serbinowski P, Hartmann R, Fujita T, Behlke MA, Williams BRG. A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol 2006; 24: 55965.